LVP, LVDevP, HR, and PRI in anesthetized rats subjected to 30 min of coronary artery occlusion followed by 120 min of reperfusion
| Group | 0 min (Pre-Occlusion) | 30 min (End-Occlusion) | 150 min (End-Reperfusion) |
|---|---|---|---|
| Sham (n= 14) | |||
| LVP (mm Hg) | 134.7 ± 6.7 | 122.5 ± 5.8 | 131.5 ± 4.7 |
| LVDevP (mm Hg) | 128.8 ± 5.7 | 117.4 ± 6.2 | 126.5 ± 5.3 |
| HR (beats/min) | 408.6 ± 8.0 | 406.9 ± 6.5 | 409.2 ± 7.6 |
| PRI (mm Hg/min × 103) | 42.8 ± 0.7 | 41.8 ± 0.6 | 42.2 ± 0.7 |
| Vehicle + MI/R (n = 19) | |||
| LVP (mm Hg) | 132.3 ± 5.1 | 120.4 ± 6.5 | 125.3 ± 3.8 |
| LVDevP (mm Hg) | 126.9 ± 7.0 | 112.5 ± 5.8 | 116.7 ± 4.2 |
| HR (beats/min) | 406.0 ± 7.8 | 424.0 ± 9.2 | 403.6 ± 8.4 |
| PRI (mm Hg/min × 103) | 42.6 ± 1.2 | 41.5 ± 1.0 | 40.3 ± 1.1 |
| NCX + MI/R (n = 14) | |||
| LVP (mm Hg) | 133.7 ± 4.7 | 123.0 ± 7.2 | 128.5 ± 6.2 |
| LVDevP (mm Hg) | 128.1 ± 4.6 | 118.2 ± 6.3 | 122.8 ± 5.5 |
| HR (beats/min) | 405.3 ± 6.1 | 412.2 ± 5.4 | 406.2 ± 4.9 |
| PRI (mm Hg/min × 103) | 41.9 ± 0.5 | 41.1 ± 1.3 | 41.6 ± 0.8 |
| ASA + MI/R (n = 14) | |||
| LVP (mm Hg) | 136.1 ± 7.5 | 121.3 ± 6.4 | 126.8 ± 4.3 |
| LVDevP (mm Hg) | 130.1 ± 6.5 | 116.7 ± 5.5 | 121.1 ± 5.6 |
| HR (beats/min) | 407.9 ± 7.9 | 416.2 ± 5.9 | 405.4 ± 6.8 |
| PRI (mm Hg/min × 103) | 42.4 ± 0.7 | 40.9 ± 1.4 | 40.1 ± 1.0 |
Vehicle (2 ml/kg PEG 400), NCX 4016 (NCX, 100 mg/kg), and ASA (54 mg/kg) were administered orally for 5 consecutive days. Data are expressed as mean ± S.E. In parentheses, number of experiments. Sham-operated animals were treated with vehicle.